ID   MH [Human ovarian carcinoma]
AC   CVCL_F845
DR   CGH-DB; 339-2
DR   Cosmic; 931365
DR   Wikidata; Q54905500
RX   PubMed=7844449;
RX   PubMed=8217948;
RX   PubMed=8375936;
RX   PubMed=17671176;
CC   Population: Japanese.
CC   Doubling time: ~6.3 days (PubMed=8217948); 36 hours (PubMed=8375936).
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C7978; Ovarian serous cystadenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   41Y
CA   Cancer cell line
DT   Created: 11-02-13; Last updated: 29-06-23; Version: 10
//
RX   PubMed=7844449;
RA   Ishii K., Kita T., Kudo K., Hisano A., Hirata J., Imaizumi E.,
RA   Tode T., Kikuchi Y., Nagata I.;
RT   "Circumvention of cisplatin resistant ovarian cancer cells by
RT   antiestrogens.";
RL   Nihon Sanka Fujinka Gakkai Zasshi 47:19-26(1995).
//
RX   PubMed=8217948;
RA   Sasa H., Hisano A., Ishii K., Hirata J., Kikuchi Y., Nagata I.,
RA   Senoo A., Aida S., Tamai S., Sugita M.;
RT   "Establishment of a cisplatin-resistant human ovarian cancer cell
RT   line.";
RL   Hum. Cell 6:106-113(1993).
//
RX   PubMed=8375936; DOI=10.1002/ijc.2910550332;
RA   Hirata J., Kikuchi Y., Kita T., Imaizumi E., Tode T., Ishii K.,
RA   Kudoh K., Nagata I.;
RT   "Modulation of sensitivity of human ovarian cancer cells to
RT   cis-diamminedichloroplatinum(II) by 12-O-tetradecanoylphorbol-13-acetate
RT   and D,L-buthionine-S,R-sulphoximine.";
RL   Int. J. Cancer 55:521-527(1993).
//
RX   PubMed=17671176; DOI=10.1158/0008-5472.CAN-06-4567;
RA   Kikuchi R., Tsuda H., Kanai Y., Kasamatsu T., Sengoku K.,
RA   Hirohashi S., Inazawa J., Imoto I.;
RT   "Promoter hypermethylation contributes to frequent inactivation of a
RT   putative conditional tumor suppressor gene connective tissue growth
RT   factor in ovarian cancer.";
RL   Cancer Res. 67:7095-7105(2007).
//